Clinical trial
Phase II Trial of REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary & Follicular Thyroid Carcinomas
NCT00287287 is registered in ClinicalTrials.gov with Kenneth Ain as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Trial of REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary & Follicular Thyroid Carcinomas
- Lead sponsor
- Kenneth Ain
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 28, 2006
- Completion date
- July 6, 2010
- Enrollment
- 25 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.